- Healthcare Professionals
- Clinical trials
- 2693-cl-1303
Astellas 2693-CL-1303
A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy.
Trial overview
Disease
Breast cancer
Topic
Diagnostics
Sponsor
Astellas Pharma
Description
A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy.
Study details
For detailed information on this trial, please click here
Trial status
Opening July 2025
Location
Principal Investigator
Dr. Rene Roux
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.